百令胶囊辅助恩替卡韦治疗干扰素无应答HBeAg阳性慢性乙型肝炎的临床研究

朱红玲; 邓卫平

doi:10.3969/j.issn.1671-038X.2017.07.05

百令胶囊辅助恩替卡韦治疗干扰素无应答HBeAg阳性慢性乙型肝炎的临床研究

朱红玲,
邓卫平^,

- 十堰市太和医院(湖北医药学院附属医院), 湖北十堰 442000
基金项目:
湖北省教育指导项目（No：B2016125）

详细信息

作者简介:
朱红玲,女,主管,本科,研究方向:消化内科肿瘤诊疗

通讯作者: 邓卫平,E-mail:dwpdenweipinjob@163.com

中图分类号: R575.1

收稿日期: 2017-01-10

Clinical study of Bailing Capsule with Entecavir in treatment of HBeAg positive chronic hepatitis B with no response to interferon

ZHU Hong-ling,
DENG Wei-ping^,

- Taihe Hospital, Hubei University of Medicine, Hubei 442000, China

More Information

Corresponding author: DENG Wei-ping, E-mail: dwpdenweipinjob@163.com

Received Date: 10 January 2017

摘要

摘要: [目的]摘要：[目的]观察中药制剂百令胶囊联用西药恩替卡韦对干扰素无应答HBeAg阳性慢性乙型肝炎（Chronic hepatitis B，CHB）的疗效，探讨中西医结合治疗该病的可能机制，为临床合理用药提供理论依据。[方法]将76例干扰素治疗无应答的CHB患者均分为对照组和中西医结合组；对照组口服恩替卡韦；中西医结合组加服百令胶囊，治疗2年。于治疗半年、1年及2年时对HBV-DNA进行定量分析并检测外周血HBsAg滴度和TGF-β_l，同时检测肝功能、免疫学和氧化应激相关指标，并计算2组HBeAg血清转换率和总有效率，籍此比较临床疗效。[结果]治疗2年时，中西医结合组HBV-DNA、HBsAg和TGF-β_l明显低于对照组（P<0.05）；药后半年、1年和2年时的检测结果中谷丙转氨酶（ALT）、谷草转氨酶（AST）、丙二醛（MDA）及肌酸磷酸激酶（CPK）均低于对照组，还原型谷胱甘肽（GSH）和超氧化物歧化酶（SOD）高于对照组（P<0.05）；在1年、2年两次检测结果中T淋巴细胞和单核细胞低于对照组，血清总蛋白、白蛋白和血红蛋白、HBeAg血清转换率及总有效率高于对照组（P<0.05）。[结论]百令胶囊联用恩替卡韦治疗CHB疗效显著。
- 干扰素无应答 /
- HBeAg阳性慢性乙型肝炎 /
- 恩替卡韦 /
- 百令胶囊 /
- 肝功能 /
- 免疫应答
Abstract: [Objective] To observe the curative effect of traditional Chinese medicine(TCM), Bailing Capsule combined with western medicine(WM), entecavir on HBeAg positive chronic hepatitis B (Chronic hepatitis, B, CHB) with non-response to interferon.Discussing the mechanism of TCM and WM combined treatment to the disease, and providing a theoretical basis for how to use drug in clinical rational way.[Methods] 76 patients who had CHB with no response to interferon were divided into control group and combined treatment group group.Control group was treated with oral administration of Entecavir.The combination of traditional Chinese medicine and Western medicine group was treated with Entecavir and Bailing Capsule for a period of 2 years.In the treatment of half a year, 1 year and 2 years, quantitative HBV-DNA, HBsAg titer and TGF- beta L in peripheral blood were obeserved, in the mean time liver function, immunological and oxidative stress related indicators, and calculated HBeAg serum conversion rate and the total efficiency were detected in the second group, in order to compare the clinical efficacy.[Results] After 2 years of treatment, HBV-DNA, HBsAg and TGF-beta l in the combined group, was significantly lower than that of the control group (P<0.05); after treatment for six months, 1 years and 2 years, alanine aminotransferase (ALT), aspartate aminotransferase(AST), malondialdehyde(MDA) and creatine kinase (CPK) in the combined treatment group were lower than that of control group, glutathione (GSH) and superoxide dismutase (SOD) were higher than that of the control group (P<0.05);after the treatment of 1 and 2years, numbers of T lymphocyte cells and Mononuclear cells in combined treatment group were lower than that in control group.Serum total protein, albumin and hemoglobin, serum HBeAg conversion rate and the total efficiency in combined treatment group were higher than that in the control group (P<0.05).[Conclusion] Bailing capsule combined with Entecavir in treatment of CHB has curative effects.
- Non response to interferon /
- HBeAg positive chronic hepatitis B /
- entecavir /
- bailing capsule /
- liver function /
- immune response

HTML全文

参考文献(18)

[1]	鲍旭丽, 渠亚超, 闾军, 等.慢性乙型肝炎抗病毒及免疫调节治疗研究进展[J].中国中西医结合消化杂志, 2016(6):484-487
[2]	朱世殊, 张鸿飞.儿童慢性乙型肝炎的抗病毒治疗[J].临床肝胆病杂志, 2015, 31(8):1211-1214.
[3]	张展.干扰素加核苷类似物治疗对乙肝患者肝细胞内HBVcccDNA和tDNA及血清hbsag的影响分析[J].中国中西医结合消化杂志, 2016(6):459-462
[4]	庄辉.2013年更新的NICE《儿童、青年和成人慢性乙型肝炎诊断和管理指南》解读[J].中国病毒病杂志, 2013, 11(6):401-405.
[5]	中国中医药学会内科肝病专业委员会.病毒性肝炎中医辨证标准(修订稿)[J].中医杂志, 1992, 295(5):39-40.
[6]	郑盛, 唐映梅, 杨晋辉, 等.血清H BsA g滴度监测对恩替卡韦治疗的H BeA g阳性慢性乙型肝炎患者应答反应的预测价值[J].实用肝脏病杂志, 2014, 17(5):502-506.
[7]	汪梦, 汤雄, 张竟, 等.恩替卡韦治疗儿童慢性乙型肝炎的疗效[J].实用临床医学, 2012, 13(1):16-18.
[8]	张仲景.金匮要略[M].学苑出版社, 2008年1月出版.
[9]	申恩华, 杜娟, 王立红, 等.血清HBsAg滴度反映恩替卡韦治疗乙型肝炎肝硬化合并原发性肝癌患者病毒应答的临床价值[J].中国医药导报, 2016, 13(17):86-88.
[10]	ZHANG HF, ZHU SS, DONG Y, et al, Efficacy and safety of telbivudinein Chinese children and adolescents with chronichepatitis B[J].2014, AASLD:1917.-1919.
[11]	白留江.干扰素治疗无应答的慢性乙型肝炎患者再治疗方法探讨[J].肝脏, 2014, 19(10):774-776.
[12]	宋艳丽, 郭俐宏, 朱克刚, 等.百令胶囊对大鼠急性肾缺血再灌注损伤的保护作用[J].陕西医学杂志, 2014, 43(1):25-27.
[13]	江雪莲, 李敏, 李莉, 等.冬虫夏草提取液对肾移植大鼠肾缺血/再灌注损伤免疫调节作用的实验研究[J].国际中医中药杂志, 2016, 5(3):10-13.
[14]	李英, 陈德森, 李莉, 等.阿拓莫兰联合百令胶囊治疗糖尿病肾病合并高血压的l临床研究[J].世界中医药, 2014, 9(3):311-313.
[15]	马青, 许青云, 郭银燕, 等.核苷类药物治疗儿童慢性乙型肝炎安全性的临床研究[J].肝脏, 2013, 18(7):446-467.
[16]	蒋开平, 陶银, 胡洪涛, 等.湿热型慢性乙型肝炎患者血清TGF-βl及TIMP-1水平的研究[J].中西医结合肝病杂志, 2007, 17(5):264-2654.
[17]	李敏, 谈国蕾.慢性乙型肝炎患者血清HBsAg浓度与HBV DNA定量及HBeAg滴度的关系分析[J].中西医结合肝病杂志, 2015, 25(1):50-52.
[18]	邹佩霞, 李敏, 李莉, 等.冬虫夏草浸出液合用硫唑嘌呤对大鼠肝移植后免疫调节的影响[J].长春中医药大学学报, 2015, 6(5):901-904.